Poor glycemic control is associated with an impaired immune response to vaccination against SARS-CoV-2 and an increased risk for breakthrough infections in people with type 2 diabetes, report researchers.
The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.